TSI

TSI TSI mission is to develop new generation products to treat thrombotic diseases: A better, safer clot buster for heart attacks and strokes.

Thrombolytic Science International (TSI) is a clinical-stage, privately-held vascular medicine and biotechnology company founded in 2006 in Cambridge, Mass., based on discoveries made in the Vascular Research Laboratory at Beth Israel Deaconess Medical Center by TSI cofounder and Harvard Medical School Professor, Victor Gurewich, M.D.

Address

Cambridge, MA

Website

Alerts

Be the first to know and let us send you an email when TSI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category